Related Experiment Video
Updated: Aug 30, 2025
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Targeting KRAS: Crossroads of Signaling and Immune Inhibition
Shumei Kato1, Yu Fujiwara2, David S Hong3
1Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USA.
Abstract:
Mutations of RAS are commonly seen in human cancers, especially in lung, colorectal, and pancreatic adenocarcinoma. Despite huge effort for decades, targeting RAS mutations has been "undruggable" because of the molecular instability of RAS protein inhibition. However, the recent discovery of the KRAS G12C inhibitor paved the way to expand therapeutic options for patients with cancer harboring the KRAS G12C mutation. At the same time, the successful development of immune checkpoint inhibitors (ICIs) drastically changed the paradigm of cancer treatment and resulted in a better understanding of the tumor immune microenvironment in patients with KRAS-mutant cancer. This review describes the following: the clinical characteristics of cancer with KRAS mutation; successful development of the KRAS G12C inhibitor and its impact on the tumor immune microenvironment; and potential new avenues such as the combination strategy using KRAS inhibitor and ICI, with preclinical and clinical rationales for overcoming resistance to inhibition of KRAS to improve therapeutic efficacy for patients with cancer harboring KRAS mutations.
Insights
Targeting KRAS mutations in cancer is now possible with KRAS G12C inhibitors. This review explores their impact on the tumor immune microenvironment and combination strategies with immune checkpoint inhibitors for improved efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- RAS mutations are prevalent in various human cancers, historically posing therapeutic challenges due to protein instability.
- The
- KRAS G12C inhibitors represent a breakthrough, offering new treatment avenues for specific KRAS-mutant cancers.
Purpose of the Study:
- To review the clinical characteristics of KRAS-mutant cancers.
- To discuss the development and impact of KRAS G12C inhibitors on the tumor immune microenvironment.
- To explore combination strategies involving KRAS inhibitors and immune checkpoint inhibitors (ICIs) for enhanced therapeutic outcomes.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of the impact of KRAS G12C inhibition on tumor immunology.
- Evaluation of combination therapy rationales and evidence.
Main Results:
- KRAS G12C inhibitors demonstrate clinical efficacy, altering the tumor immune microenvironment.
- Combination strategies show promise in preclinical models for overcoming resistance.
- Understanding KRAS-mutant cancer's immune landscape is crucial for treatment success.
Conclusions:
- Targeting KRAS G12C mutations is a viable therapeutic strategy.
- Combining KRAS inhibitors with ICIs offers a promising approach to improve efficacy in KRAS-mutant cancers.
- Further research into combination therapies is warranted to overcome resistance and enhance patient outcomes.
Related Concept Videos
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:20The JAK-STAT Signaling Pathway
01:31Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...